UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 118

Sortiert nach

Challenges and pitfalls of combining targeted agents in phase I studies

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3665-3667

Cannistra, Stephen A

2008

Volltextzugriff (PDF)

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer

Endocrine-related cancer, 2007-09, Vol.14 (3), p.781-790

2007

Volltextzugriff (PDF)

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

BMC medical genomics, 2008-11, Vol.1 (1), p.59-59

2008

Volltextzugriff (PDF)

Gene-expression profiling in epithelial ovarian cancer

Nature clinical practice. Oncology, 2008-10, Vol.5 (10), p.577-587

2008

Volltextzugriff (PDF)

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer

Journal of clinical oncology, 2014-05, Vol.32 (13), p.1287-1289

2014

Volltextzugriff (PDF)

Intraperitoneal Chemotherapy Comes of Age

The New England journal of medicine, 2006-01, Vol.354 (1), p.77-79

Cannistra, Stephen A

2006

Volltextzugriff (PDF)

New initiatives at Journal of Clinical Oncology

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2609-2610

Cannistra, Stephen A

2011

Volltextzugriff (PDF)

Evaluation of treatment benefit in Journal of Clinical Oncology

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1123-1124

2013

Volltextzugriff (PDF)

The ethics of early stopping rules: Who is protecting whom?

Journal of clinical oncology, 2004-05, Vol.22 (9), p.1542-1545

CANNISTRA, Stephen A

2004

Volltextzugriff (PDF)

Phase I studies of drug combinations

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4545-4546

2010

Volltextzugriff (PDF)

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial

Journal of clinical oncology, 2012-02, Vol.30 (4), p.347-350

2012

Volltextzugriff (PDF)

Laparoscopic Intraperitoneal Port Placement for Optimally Cytoreduced Advanced Ovarian Cancer

Journal of minimally invasive gynecology, 2011-09, Vol.18 (5), p.629-633

2011

Volltextzugriff (PDF)

Performance of biopsies in clinical research

Journal of clinical oncology, 2007-04, Vol.25 (11), p.1454-1455

Cannistra, Stephen A

2007

Volltextzugriff (PDF)

Cancer of the Ovary

The New England journal of medicine, 1993-11, Vol.329 (21), p.1550-1559

Cannistra, Stephen A

1993

Volltextzugriff (PDF)

Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas

The American journal of pathology, 2001-06, Vol.158 (6), p.2097-2106

2001

Volltextzugriff (PDF)

Advances in the management of epithelial ovarian cancer

Journal of reproductive medicine, 2005-06, Vol.50 (6), p.426

2005

Volltextzugriff (PDF)

Gynecologic oncology or medical oncology: what's in a name?

Journal of clinical oncology, 2007-04, Vol.25 (10), p.1157-1159

Cannistra, Stephen A

2007

Volltextzugriff (PDF)

BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease

Clinical cancer research, 2007-12, Vol.13 (24), p.7225-7227

Cannistra, Stephen A

2007

Volltextzugriff (PDF)

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1158-1160

Cannistra, Stephen A

2002

Volltextzugriff (PDF)

Reply to C.M. Booth et al

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3300-3300

2013

Volltextzugriff (PDF)

Cancer of the Uterine Cervix

The New England journal of medicine, 1996-04, Vol.334 (16), p.1030-1037

1996

Volltextzugriff (PDF)

Bevacizumab rechallenge after first line maintenance bevacizumab

Gynecologic oncology, 2012-05, Vol.125 (2), p.510-511

2012

Volltextzugriff (PDF)

In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice : A novel role for CD44 in the process of peritoneal implantation

Cancer research (Chicago, Ill.), 1997-04, Vol.57 (7), p.1228-1232

1997

Volltextzugriff (PDF)

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene

Cancer research (Chicago, Ill.), 1999-05, Vol.59 (9), p.2121-2126

1999

Volltextzugriff (PDF)

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

Gynecologic oncology, 2004-12, Vol.95 (3), p.624-631

2004

Volltextzugriff (PDF)

26 – 50 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(117)
Buchkapitel
(1)

Sprache

Englisch
(118)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Humans
(84)
Life Sciences & Biomedicine
(82)
Female
(57)
Oncology
(57)
Biological And Medical Sciences
(46)
Medical Sciences
(34)
Tumors
(25)
Ovarian Neoplasms - Drug Therapy
(22)
Female Genital Diseases
(21)
Gynecology. Andrology. Obstetrics
(21)
Middle Aged
(21)
Ovarian Neoplasms - Pathology
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Ovarian Cancer
(17)
Adult
(16)
Aged
(15)
Ovarian Neoplasms - Genetics
(14)
Treatment Outcome
(13)
Fundamental And Applied Biological Sciences. Psychology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Challenges and pitfalls of combining targeted agents in phase I studies

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer

Gene-expression profiling in epithelial ovarian cancer

Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer

Intraperitoneal Chemotherapy Comes of Age

New initiatives at Journal of Clinical Oncology

Evaluation of treatment benefit in Journal of Clinical Oncology

The ethics of early stopping rules: Who is protecting whom?

Phase I studies of drug combinations

Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial

Laparoscopic Intraperitoneal Port Placement for Optimally Cytoreduced Advanced Ovarian Cancer

Performance of biopsies in clinical research

Cancer of the Ovary

Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas

Advances in the management of epithelial ovarian cancer

Gynecologic oncology or medical oncology: what's in a name?

BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

Reply to C.M. Booth et al

Cancer of the Uterine Cervix

Bevacizumab rechallenge after first line maintenance bevacizumab

In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice : A novel role for CD44 in the process of peritoneal implantation

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

Suchergebnisse filtern